Detalhe da pesquisa
1.
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lancet
; 402(10400): 451-463, 2023 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37423228
2.
Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma.
BMC Cancer
; 24(1): 94, 2024 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38233752
3.
Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients.
BMC Cancer
; 24(1): 269, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38408928
4.
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.
Mol Cancer
; 22(1): 124, 2023 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37543587
5.
Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.
BMC Cancer
; 23(1): 1244, 2023 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104105
6.
Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
Anticancer Drugs
; 34(9): 1058-1064, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37265026
7.
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.
BMC Med
; 20(1): 453, 2022 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36424628
8.
Prognostic Significance of Combined Biomarkers in Small Cell Lung Cancer.
Clin Lab
; 66(9)2020 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32902217
9.
Tumor necrosis factor superfamily 15 promotes lymphatic metastasis via upregulation of vascular endothelial growth factor-C in a mouse model of lung cancer.
Cancer Sci
; 109(8): 2469-2478, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29890027
10.
Exosomal miR-27a Derived from Gastric Cancer Cells Regulates the Transformation of Fibroblasts into Cancer-Associated Fibroblasts.
Cell Physiol Biochem
; 49(3): 869-883, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30184548
11.
miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer.
Tumour Biol
; 39(6): 1010428317701636, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28618968
12.
Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.
Jpn J Clin Oncol
; 46(4): 336-43, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26819278
13.
miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer.
J Cell Biochem
; 115(3): 549-56, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24122958
14.
The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer.
Platelets
; 25(5): 382-7, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24001199
15.
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.
J Thorac Oncol
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38460751
16.
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
Lung Cancer
; 188: 107455, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38224653
17.
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Thorac Cancer
; 15(5): 419-426, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38219795
18.
Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis.
Front Oncol
; 13: 1128443, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36950551
19.
Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer.
J Comp Eff Res
; 12(5): e230006, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37067955
20.
The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer.
Cancer Med
; 12(16): 17403-17412, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37587845